CureVac N.V. Form 6-K (April 19, 2021)

Summary

A Form 6-K report of foreign private issuer filed by CureVac N.V. with the U.S. Securities and Exchange Commission for the month of April, 2021, Commission File Number 001-39446. It states that on April 19, 2021 the company issued a press release announcing the initiation of a rolling submission for its mRNA based COVID-19 vaccine candidate, CVnCoV, for use in Switzerland. The press release is listed as Exhibit 99.1, and the report is signed by Franz-Werner Haas, LLD, LLM, Chief Executive Officer.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.
20549

FORM 6-K

REPORT
OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16
OR 15d-16 OF THE

SECURITIES EXCHANGE ACT
OF 1934

For the month of April, 2021

Commission File
Number: 001-39446

CureVac N.V.

( Exact Name of Registrant as Specified in Its
Charter )

Friedrich-Miescher-Strasse 15, 72076

Tübingen, Germany

+49 7071 9883 0

(Address of principal executive office)

Indicate by check mark whether the registrant files
or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F | x | Form 40-F | ¨

Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes | ¨ | No | x

Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes | ¨ | No | x

On April 19, 2021, CureVac N.V. (the “Company”)
issued a press release announcing the initiation of a rolling submission for the Company’s mRNA based COVID-19 vaccine candidate,
CVnCoV, for use in Switzerland.

The information in this Form 6-K (including Exhibit
99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”)
or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities
Act of 1933 or the Exchange Act.

SIGNATURES

Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

CUREVAC N.V.
By: | /s/ Franz-Werner Haas, LLD, LLM
Chief Executive Officer

Date: April 19, 2021

EXHIBIT INDEX

EXHIBIT NO. | DESCRIPTION
99.1 | CureVac N.V. Press Release dated April 19, 2021.

File and source

File

SEC_CVAC_6-K_filed2021-04-19_0001104659-21-051615.htm

Size

13,951 bytes

SHA-256

9da8c59e3a009e7d5139235b9484d35a7cf0755516b18f7368918e82b028c451

Our copy

SEC_CVAC_6-K_filed2021-04-19_0001104659-21-051615.htm

Original

www.sec.gov